Reference is made to the stock exchange announcement made by Circio Holding
ASA (the "Company") on 8 April 2026, regarding key information relating to a
potential subsequent offering of up to 7,638,888 new shares in the Company
(the "Subsequent Offering").

The shares in the Company will be traded exclusive of the right to participate
in the subsequent Offering from and including today, 8 April 2026.

Ex. date: 8 April 2026

* * *

This information is published in accordance with the requirements of the
Continuing Obligations in Euronext Rule Book II.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.